Instituto Nacional de Investigação em Saúde (INIS), Luanda, Angola.
Instituto Superior de Ciências de Saúde (ISCISA), Universidade Agostinho Neto (UAN), Luanda, Angola.
PLoS One. 2022 May 5;17(5):e0267671. doi: 10.1371/journal.pone.0267671. eCollection 2022.
Despite the guidelines provided by the World Health Organization for the treatment of malaria, treatment failure occurs in many hospitalized patients.
Evaluate whether blood cell count parameters may serve as predictors for malaria treatment.
A cross-sectional study with a quantitative approach.
Of the 219 patients, 21.5% showed failure to antimalarial treatment, Patient with 21 and 40 years (72.6%), male (53.4%), from peri-urban area (47.5%), with high parasitemia (59.8%), treated with Arthemeter (90.9%) and the mortality were 5.9%. Significant associations were observed between occupation, level of parasitemia and outcome with resistance to antimalarial treatment (p<0.05). Patients with normal Hb [OR: 0.75 (95% CI: 0.39-1.44), p = 0.393], RBC [OR: 0.83 (95% CI: 0.40-1.72), p = 0.632], RDW [OR: 0.54 (95% CI: 0.27-1.09), p = 0.088], MCV [OR: 0.61 (95% CI: 0.28-1.31), p = 0.204] were less likely to have malaria treatment failures after artemisinin-based therapy failure. In contrast, those with normal values of segmented neutrophils [OR: 0.32 (95% CI: 0.11-0.96), p = 0.042] and lymphocyte counts [OR: 0.24 (95% CI: 0.05-1.04), p = 0.055]. We also found that patients with significant low levels of Hct [OR: 0.31 (95% CI: 0.15-0.64) p = 0.002], and high leukocytes [OR: 8.88 (95% CI: 2.02-37.2), p = 0.004] and normal platelet values [OR: 1.42 (95% CI: 0.73-2.95), p = 0.280] demonstrated high probability of treatment failure.
The importance of blood cell count parameters in monitoring malaria therapy necessitates the urgent need to re-evaluate Artemether-based therapy. Future studies involving more participants in different settings are needed to provide further evidence.
尽管世界卫生组织为疟疾治疗提供了指南,但许多住院患者的治疗仍以失败告终。
评估血细胞计数参数是否可作为疟疾治疗的预测指标。
一项采用定量方法的横断面研究。
在 219 名患者中,21.5%的患者抗疟治疗失败,患者年龄 21-40 岁(72.6%),男性(53.4%),来自城市周边地区(47.5%),高疟原虫血症(59.8%),采用蒿甲醚治疗(90.9%),死亡率为 5.9%。职业、疟原虫水平和结局与抗疟治疗耐药性之间存在显著相关性(p<0.05)。血红蛋白正常的患者[比值比(OR):0.75(95%置信区间:0.39-1.44),p=0.393]、红细胞计数正常的患者[OR:0.83(95%置信区间:0.40-1.72),p=0.632]、红细胞分布宽度正常的患者[OR:0.54(95%置信区间:0.27-1.09),p=0.088]、平均红细胞体积正常的患者[OR:0.61(95%置信区间:0.28-1.31),p=0.204]发生抗疟治疗失败的可能性较小。相比之下,中性粒细胞分段值正常的患者[OR:0.32(95%置信区间:0.11-0.96),p=0.042]和淋巴细胞计数正常的患者[OR:0.24(95%置信区间:0.05-1.04),p=0.055]发生抗疟治疗失败的可能性较小。我们还发现,血细胞比容显著降低的患者[OR:0.31(95%置信区间:0.15-0.64),p=0.002]、白细胞计数升高的患者[OR:8.88(95%置信区间:2.02-37.2),p=0.004]和血小板计数正常的患者[OR:1.42(95%置信区间:0.73-2.95),p=0.280]发生抗疟治疗失败的可能性较大。
监测疟疾治疗时血细胞计数参数的重要性需要重新评估基于蒿甲醚的治疗。需要在不同环境中纳入更多参与者的进一步研究提供进一步的证据。